Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Seenappa LM"'
Autor:
Drakes DJ; Elicio Therapeutics, Boston, Massachusetts., Abbas AM; Elicio Therapeutics, Boston, Massachusetts., Shields J; Elicio Therapeutics, Boston, Massachusetts., Steinbuck MP; Elicio Therapeutics, Boston, Massachusetts., Jakubowski A; Elicio Therapeutics, Boston, Massachusetts., Seenappa LM; Elicio Therapeutics, Boston, Massachusetts., Haqq CM; Elicio Therapeutics, Boston, Massachusetts., DeMuth PC; Elicio Therapeutics, Boston, Massachusetts.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2024 Feb 02; Vol. 12 (2), pp. 214-231.
Autor:
Pant S; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. spant@mdanderson.org., Wainberg ZA; University of California, Los Angeles, Los Angeles, CA, USA., Weekes CD; Massachusetts General Hospital, Boston, MA, USA., Furqan M; University of Iowa, Iowa City, IA, USA., Kasi PM; University of Iowa, Iowa City, IA, USA., Devoe CE; Northwell Health, Lake Success, NY, USA., Leal AD; University of Colorado School of Medicine, Aurora, CO, USA., Chung V; City of Hope, Duarte, CA, USA., Basturk O; Memorial Sloan Kettering Cancer Center, New York, NY, USA., VanWyk H; Elicio Therapeutics, Boston, MA, USA., Tavares AM; Elicio Therapeutics, Boston, MA, USA., Seenappa LM; Elicio Therapeutics, Boston, MA, USA., Perry JR; Elicio Therapeutics, Boston, MA, USA., Kheoh T; Elicio Therapeutics, Boston, MA, USA., McNeil LK; Elicio Therapeutics, Boston, MA, USA., Welkowsky E; Elicio Therapeutics, Boston, MA, USA., DeMuth PC; Elicio Therapeutics, Boston, MA, USA., Haqq CM; Elicio Therapeutics, Boston, MA, USA. chris.haqq@elicio.com., O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, NY, USA. oreillye@mskcc.org.
Publikováno v:
Nature medicine [Nat Med] 2024 Feb; Vol. 30 (2), pp. 531-542. Date of Electronic Publication: 2024 Jan 09.
Autor:
Dasari V; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia. vijayendra.dasari@qimr.edu.au., McNeil LK; Elicio Therapeutics, Inc, Boston, MA, USA., Beckett K; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia., Solomon M; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia., Ambalathingal G; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia., Thuy TL; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia., Panikkar A; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia., Smith C; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia., Steinbuck MP; Elicio Therapeutics, Inc, Boston, MA, USA., Jakubowski A; Elicio Therapeutics, Inc, Boston, MA, USA., Seenappa LM; Elicio Therapeutics, Inc, Boston, MA, USA., Palmer E; Elicio Therapeutics, Inc, Boston, MA, USA., Zhang J; Elicio Therapeutics, Inc, Boston, MA, USA., Haqq CM; Elicio Therapeutics, Inc, Boston, MA, USA., DeMuth PC; Elicio Therapeutics, Inc, Boston, MA, USA., Khanna R; QIMR Centre for Immunotherapy and Vaccine Development, Tumour Immunology Laboratory, Infection and Inflammation Program, Berghofer Medical Research Institute, Brisbane, Australia. rajiv.khanna@qimr.edu.au.
Publikováno v:
Nature communications [Nat Commun] 2023 Aug 08; Vol. 14 (1), pp. 4371. Date of Electronic Publication: 2023 Aug 08.
Autor:
Seenappa LM; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA., Jakubowski A; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA., Steinbuck MP; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA., Palmer E; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA., Haqq CM; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA., Carter C; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, 70560, LA, USA., Fontenot J; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, 70560, LA, USA., Villinger F; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, 70560, LA, USA., McNeil LK; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA., DeMuth PC; Elicio Therapeutics, 451 D Street, 5th Floor, Suite 501, Boston, 02210, MA, USA. pete.demuth@elicio.com.
Publikováno v:
NPJ vaccines [NPJ Vaccines] 2022 Oct 28; Vol. 7 (1), pp. 128. Date of Electronic Publication: 2022 Oct 28.
A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Autor:
Steinbuck MP; Elicio Therapeutics, One Kendall Square, Suite 14303, Cambridge, MA 02139, USA., Seenappa LM; Elicio Therapeutics, One Kendall Square, Suite 14303, Cambridge, MA 02139, USA., Jakubowski A; Elicio Therapeutics, One Kendall Square, Suite 14303, Cambridge, MA 02139, USA., McNeil LK; Elicio Therapeutics, One Kendall Square, Suite 14303, Cambridge, MA 02139, USA., Haqq CM; Elicio Therapeutics, One Kendall Square, Suite 14303, Cambridge, MA 02139, USA. chris.haqq@elicio.com., DeMuth PC; Elicio Therapeutics, One Kendall Square, Suite 14303, Cambridge, MA 02139, USA.
Publikováno v:
Science advances [Sci Adv] 2021 Feb 05; Vol. 7 (6). Date of Electronic Publication: 2021 Feb 05 (Print Publication: 2021).